Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
Financings

Optimi Health Announces Proposed Nasdaq Listing and U.S. Underwritten Public Offering

By The Northwire Desk — AI Analysis Mar 16, 2026 · 07:01 OPTI · 0.295 Optimi Health Corp.
OPTI · Price

Executive Summary

  • Optimi Health Corp. announced the commencement of an underwritten public offering of its common shares in the United States, intended to support a proposed Nasdaq Capital Market listing.
  • The company will effect a 30‑for‑1 reverse share consolidation prior to the effectiveness of the registration statement to meet Nasdaq’s minimum price requirement, reducing outstanding shares from ~96.8 M to ~3.23 M.
  • Joseph Gunnar & Co., LLC is acting as sole book‑running manager; the offering size and pricing remain undisclosed pending SEC effectiveness and market conditions.

Key Details

  • Offering Structure: Underwritten public offering of common shares (no par value) in the U.S.; prospectus to be filed with the SEC under a registration statement that has not yet become effective.
  • Underwriter: Joseph Gunnar & Co., LLC – sole book‑running manager.
  • Nasdaq Listing Goal: Application submitted to list on Nasdaq under ticker “OPTH” pending approval; shares will continue trading on the CSE.
  • Share Consolidation: 1 post‑consolidation share for every 30 pre‑consolidation shares (30:1 reverse split).
  • Pre‑consolidation outstanding shares: 96,776,919.
  • Post‑consolidation expected outstanding shares: ~3,225,897 (before rounding and fractional adjustments).
  • Purpose of Consolidation: To satisfy Nasdaq’s minimum share price requirement; will not alter proportional ownership aside from fractional share treatment.
  • Adjustments to Derivatives: All outstanding incentive stock options, warrants, and convertible securities will be adjusted on a 30:1 basis, including exercise prices.
  • Regulatory & Offering Conditions:
  • Offering subject to market conditions, SEC effectiveness, Nasdaq review, and customary closing conditions.
  • Shares not being offered to Canadian residents; any Canadian offering would require separate prospectus exemptions.
  • Share Identifiers Post‑Consolidation: New CUSIP = 68405H308; new ISIN = CA68405H3080.
  • Board Approval: Consolidation approved at the annual general and special meeting of shareholders on 8 Sept 2025; no further shareholder action required.
  • Contact Information: CEO Dane Stevens ([email protected]) and Investor Relations contact Lucas A. Zimmerman, MZ Group.

Notable Quotes

  • “The consolidation is intended to allow the Company to meet the minimum share price requirement of the Nasdaq and is being undertaken in connection with our proposed listing on Nasdaq.” – JJ Wilson, Chairman (on behalf of the Board)
Read the original news release →

More from Optimi Health Corp.

Jun 29, 2026 · 09:00

Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression

Production / Operations Jun 16, 2026 · 08:30

Vertically integrated GMP psychedelic manufacturer scaling clinical supply, but revenue remains negligible and execution is incremental.

Production / Operations Jun 10, 2026 · 09:15

Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial

Production / Operations Jun 08, 2026 · 08:00

Psychedelic GMP manufacturer advances ibogaine development amid US policy tailwinds, but commercial revenue remains negligible.

Regulatory Jun 02, 2026 · 07:30

Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia

Production / Operations May 29, 2026 · 08:30

Australia widens insurance-backed psychedelic therapy access — Optimi’s existing supply chain gains yet another tailwind, but market still awaits proof-of-revenue.

Regulatory